Newby DE - Search Results

1

Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans.

Gudmundsdóttir IJ, Lang NN, Boon NA, Ludlam CA, Webb DJ, Fox KA, Newby DE. Gudmundsdóttir IJ, et al. Among authors: newby de. J Am Coll Cardiol. 2008 May 6;51(18):1749-56. doi: 10.1016/j.jacc.2007.12.047. J Am Coll Cardiol. 2008. PMID: 18452780 Free article.

2

Enalapril overdose and the corrective effect of intravenous angiotensin II.

Newby DE, Lee MR, Gray AJ, Boon NA. Newby DE, et al. Br J Clin Pharmacol. 1995 Jul;40(1):103-4. doi: 10.1111/j.1365-2125.1995.tb04546.x. Br J Clin Pharmacol. 1995. PMID: 8527259 Free PMC article. No abstract available.

3

Advances in clinical pharmacology and therapeutics: endothelin.

Newby DE, Webb DJ. Newby DE, et al. Br J Hosp Med. 1996 Oct 2-15;56(7):360-4. Br J Hosp Med. 1996. PMID: 8899226 Review.

4

Caffeine restriction has no role in the management of patients with symptomatic idiopathic ventricular premature beats.

Newby DE, Neilson JM, Jarvie DR, Boon NA. Newby DE, et al. Heart. 1996 Oct;76(4):355-7. doi: 10.1136/hrt.76.4.355. Heart. 1996. PMID: 8983684 Free PMC article. Clinical Trial.

5

The endothelin system in cardiovascular disease.

Newby DE, Webb DJ. Newby DE, et al. BMJ. 1997 Feb 22;314(7080):531-2. doi: 10.1136/bmj.314.7080.531. BMJ. 1997. PMID: 9055700 Free PMC article. No abstract available.

6

Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide.

Newby DE, Boon NA, Webb DJ. Newby DE, et al. Clin Sci (Lond). 1997 Feb;92(2):133-8. doi: 10.1042/cs0920133. Clin Sci (Lond). 1997. PMID: 9059313 Clinical Trial.

7

Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability.

Newby DE, Sciberras DG, Mendel CM, Gertz BJ, Boon NA, Webb DJ. Newby DE, et al. Br J Clin Pharmacol. 1997 May;43(5):493-9. doi: 10.1046/j.1365-2125.1997.00583.x. Br J Clin Pharmacol. 1997. PMID: 9159564 Free PMC article. Clinical Trial.

8

Endogenous angiotensin II does not contribute to sympathetic venoconstriction in dorsal hand veins of healthy humans.

Masumori S, Newby DE, Strachan FE, Boon NA, Webb DJ. Masumori S, et al. Among authors: newby de. Clin Pharmacol Ther. 1997 Sep;62(3):327-33. doi: 10.1016/S0009-9236(97)90036-9. Clin Pharmacol Ther. 1997. PMID: 9333109 Clinical Trial.

9

The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction.

Ferro CJ, Haynes WG, Johnston NR, Lomax CC, Newby DE, Webb DJ. Ferro CJ, et al. Among authors: newby de. Br J Clin Pharmacol. 1997 Oct;44(4):377-83. doi: 10.1046/j.1365-2125.1997.00595.x. Br J Clin Pharmacol. 1997. PMID: 9354313 Free PMC article. Clinical Trial.

10

An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium.

Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. Newby DE, et al. Thromb Haemost. 1997 Oct;78(4):1242-8. Thromb Haemost. 1997. PMID: 9364992

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

868 results

Search Page

Filters